Cresp 40mcg 0.4ml Injection PFS

Cresp 40mcg 0.4ml Injection PFS contains Darbepoetin Alfa 40mcg, an erythropoiesis-stimulating agent used to treat anemia associated with chronic kidney disease and chemotherapy.

Benefits

Cresp 40mcg 0.4ml Injection helps manage anemia by stimulating the bone marrow to produce more red blood cells, thereby increasing hemoglobin levels and improving oxygen supply in the body. This can reduce symptoms like fatigue, weakness, breathlessness, and dizziness, and may minimize the need for frequent blood transfusions.

Uses and Indications

• Treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults and pediatric patients, including those on dialysis and not on dialysis.
• Treatment of symptomatic anemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

The Cresp 40mcg 0.4ml Injection PFS contains:

• Darbepoetin Alfa 40mcg (active ingredient).
• Excipients: Sodium phosphate monobasic monohydrate, Sodium phosphate dibasic anhydrous, Sodium chloride, Polysorbate 80, and Water for injection.

Dosage and Administration

1. Cresp 40mcg 0.4ml Injection must be administered only by a qualified healthcare professional.
2. Do not self-administer.
3. The dose and frequency of administration (subcutaneous or intravenous) will be determined by the prescribing doctor based on the patient's condition and hemoglobin levels.
4. Hemoglobin levels should be monitored regularly during treatment.
5. For subcutaneous administration, injection sites should be rotated as instructed to reduce local reactions.

Storage and Disposal

• Store Cresp 40mcg 0.4ml Injection in a refrigerator between 2°C to 8°C.
• Keep it dry and protected from direct sunlight and moisture.
• Do not freeze.
• Dispose of used syringes safely in a puncture-proof container as per hospital guidelines.
• Keep out of reach of children.

Precautions and Safety

• Cresp 40mcg 0.4ml Injection should be used with utmost care and under the supervision of a healthcare professional experienced in this medical therapy.
• Patients should be monitored closely to ensure the lowest effective dose is used to control anemia symptoms while maintaining hemoglobin levels within the target range (typically not exceeding 10-12 g/dL), as higher hemoglobin targets may increase risks.
• Regular monitoring of blood pressure is important, as high blood pressure can be a side effect.
• Evaluate other causes of anemia before and during treatment.

Side Effects and Risks

• Possible side effects include high blood pressure and hypersensitivity reactions.
• Serious adverse cardiovascular reactions, stroke, and increased risk of death have been observed in controlled trials when erythropoiesis-stimulating agents (ESAs) were administered to target hemoglobin levels greater than 11 g/dL.
• In clinical studies of cancer patients, ESAs have been associated with shortened overall survival and/or increased risk of tumor progression or recurrence.
• Contact a doctor immediately if severe headache, chest pain, sudden weakness, breathing difficulty, severe swelling, or worsening blood pressure occurs.

Disclaimer

Use this medicine only under the prescription and guidance of a qualified doctor or pharmacist.